Current status of targeted treatment for advanced renal carcinoma in China
10.3969/j.issn.1000-8179.2017.24.918
- VernacularTitle:中国晚期肾癌靶向治疗的现状
- Author:
Jianhui MA
1
Author Information
1. 国家癌症中心/中国医学科学院北京协和医学院肿瘤医院 北京市100021
- Keywords:
advanced renal carcinoma;
targeted treatment;
current status
- From:
Chinese Journal of Clinical Oncology
2017;44(24):1223-1225
- CountryChina
- Language:Chinese
-
Abstract:
Targeted treatment for tumors is based on the molecular biological aspects of a tumor. Identifying tumor-associated mole-cules as targets and then creating molecular preparations based on these targets is the goal of drug treatment and targeted therapy. Treatment for advanced renal carcinoma has evolved since the era of targeted therapy began eleven years ago when sorafenib was ap-proved in China in September, 2006. This article reviews the development of molecular targeted treatment for tumors, discuss the effi-cacy of vascular endothelial growth factor (VEGF) inhibitors for the treatment of advanced renal carcinoma, evaluate the problems aris-ing from clinical experiences, and put forward some suggestions for targeted treatment of advanced renal carcinoma.
